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Malignant hyperthermia in a
regional facility: A case study
Abstract
Malignant hyperthermia (MH) is a rare hypermetabolic state that may
be triggered by both anaesthesia and non-anaesthesia triggers. The
main anaesthesia triggers for MH are the depolarising muscle relaxant
suxamethonium and volatile anaesthetic gases. MH presents in several ways
with not all clinical symptoms being required to make a diagnosis. Safe and
efficient patient management of MH requires knowledge and understanding
of this inherited disorder. The perioperative team need to be aware of the
tasks that are required to manage this emergency. This case study will discuss
a suspected episode of MH presenting in a patient late on Christmas Eve
2018 in a regional facility. Access to the reversal drug dantrolene provided
an additional challenge. The increase in knowledge gained by nursing
staff involved in the management of this crisis proved to be a significant
learning curve for all involved. It is hoped that this paper will enable other
perioperative nurses to benefit from this experience.
Keywords: malignant hyperthermia, anaesthetic, regional facility, dantrolene,
nursing management

Background
Malignant hyperthermia may be defined as a hypermetabolic state triggered
under general anaesthetic by volatile anaesthetic gases and the depolarising
muscle relaxant suxamethonium1. These drugs trigger uncontrolled levels of
intracellular calcium released from the sarcoplasmic reticulum within muscle
cells in the susceptible person2. Persistent muscle contraction results in
body rigidity, raised core temperature and increased cellular oxygen demand
and thus carbon dioxide production3. If not treated quickly and effectively,
cell death, organ failure, brain injury or cardiac arrest may result4. Many
perioperative nurses will never experience an episode of MH as it occurs
infrequentlyy5. MH is triggered by specific drugs which are often used to
undertake general anaesthesia6. Perioperative nurses must be familiar with
the trigger agents, presenting signs and management of MH to avoid the lifethreatening complications that can develop3,7.
This suspected case study describes the presentation of the patient’s journey
and improvements that have been made since this episode, which took place
in regional Queensland. This case study will present the challenges faced by
an after-hours perioperative team with a patient undergoing an emergency
laparoscopic appendicectomy in the late hours of Christmas Eve 2018.

Case presentation
The case being presented occurred
during an emergency laparoscopic
appendicectomy on a 32-year-old
male who will be referred to as
Mr M. Initially Mr M presented to
his general practitioner with periumbilical pain and vomiting. Acute

appendicitis was confirmed via
computed tomography (CT) scan.
Mr M was admitted to hospital and
to the operating suite for emergency
appendicectomy at 9.05 pm. The
anaesthetist performed a thorough
pre-anaesthetic assessment of the
patient on arrival. Mr M denied any
known drug allergies, medical history
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or knowledge of rare anaesthetic
reactions within his family. The
patient’s history involved previous
surgeries including removal of
wisdom teeth under general
anaesthetic and yearly colonoscopies
due to a familial history of Peutz
Jegher’s syndrome (bowel polyps).
During all these procedures, no
hypermetabolic reaction was
observed. The patient was considered
to be an otherwise healthy adult
male and had given their consent for
surgery and anaesthesia.
A rapid sequence induction was
chosen for the patient due to
a possible risk of aspiration of
gastric contents. The patient was
administered intravenous propofol,
alfentanil and rocuronium at
induction with cricoid pressure to
protect the airway. Rocuronium is a
non-depolarising muscle relaxant
that is used for its quick onset to
create optimal intubating conditions8.
Following an uneventful induction
and intubation, the inhalation
anaesthetic gas desflurane was
turned on and administered at
six per cent for maintenance of
anaesthesia. Oxycodone was titrated
during the surgery for pain relief.
The patient displayed no adverse
reactions and the surgery was
completed without any complications.
On completion of the surgery, the
volatile anaesthetic agent was
switched off and muscle relaxant
reversal drugs neostigmine and
atropine were intravenously
administered. It was noted that the
patient was slow to emerge from
anaesthesia. During the emergence
phase the patient became rigid,
cyanotic, tachycardic, hypertensive
and shook violently. He showed a
marked increase in his end-tidal
carbon dioxide (CO2) levels from 45
to 92 mm Hg (normal end-tidal CO2 is
35–45mm Hg). A tympanic membrane
thermometer recorded the patient
temperature as 40° C. Rises in end-
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tidal CO2 levels, muscle rigidity and
an increase in body temperature
are all clinical indicators of an MH
episode9. The anaesthetist surmised
that the patient was experiencing an
MH crisis as the patient symptoms
matched multiple common
symptoms of this rare disorder. An
emergency code was called. The
patient was re-anaesthetised with
an intravenous infusion of propofol.
The MH resource box was accessed
along with the cardiac arrest trolley.
Malignant Hyperthermia Group of
Australia and New Zealand (MHANZ)
task cards were handed out to the
theatre and recovery team members.
When the emergency was called,
the medical emergency team were
attending another case and could
not immediately assist. The theatre
team followed the instructions
on the MHANZ cards until further
help arrived. Ice was collected
from the kitchen, cold bags of fluid
where accessed and the theatre
temperature was decreased to help
cool the patient. Hospital stocks of
intravenous dantrolene were sourced
and mixing of the drug commenced.
The surgeon informed the patient’s
family of the emergency, initially
by telephone. The family were in
the facility during the crisis and
were kept updated on the patient’s
condition by the surgeon while the
patient was in theatre and upon
transfer to the intensive care unit.

Investigations
There is no immediate investigation
that could have been performed to
determine if MH was the cause of
the patient’s clinical symptoms. The
initial management of the crisis was
to discontinue triggering agents and
treat symptoms by administering
dantrolene and lowering the patient’s
body temperature10. Genetic testing
and fresh muscle biopsy can detect
genetic mutations11. All patients who
have a significant reaction should

be referred for further investigation
but, keeping this in mind, repeated
exposure to causative factors can
often trigger further episodes12. The
availability of testing locations is a
factor to be taken into consideration
as there are only three locations
in Australia that conduct the invitro contracture test1. If the patient
needs to undergo surgery in the
interim, volatile anaesthetic gases
and suxamethonium will need to
be avoided. Muscle biopsy testing
has not yet been performed on
this patient as the patient’s wife
gave birth to a pre-term baby
early in 2019 taking priority in their
understandably very busy lives.

Differential diagnosis
Anaesthetists must use their
expertise and clinical knowledge
to determine whether a patient’s
symptoms align with a diagnosis of
MH13. During the case, equipment
malfunction was ruled out as the
cause of rising end-tidal CO2 levels,
as the ventilator and ventilator
settings were assessed and
considered fully functional. The
soda lime canister was still within
its holding capacity. Serotonin
syndrome and neuroleptic
malignant syndromes were
excluded as the patient reported
nil current medications. These
syndromes typically present as
a reaction to antidepressant and
antipsychotic medications and show
similar symptoms to malignant
hyperthermia 2,14. Serotonin syndrome
does not present with a fever 14.
There are multiple clinical signs and
symptoms of a MH event; however,
not all clinical indicators need to
be observed for the anaesthetist
to determine a MH diagnosis1. If a
patient has received a triggering
agent and has symptoms, then
MH should be considered as a
differential diagnosis2. Immediate
treatment is recommended to
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avoid cell death and possible
cardiac arrest15. Dantrolene is a
safe medication when given with
appropriate ventilatory support1.
The patient subsequently displayed
further episodes of fever, unstable
blood pressure and muscle rigidity,
requiring further doses and continual
infusion of dantrolene while
intubated in the intensive care unit.

Treatment
On the completion of surgery, endtidal CO2 levels had risen from 45 to
92 mm Hg. This was an indication
that the body was experiencing
increased oxygen consumption, thus
increased CO2 expulsion due to the
hypermetabolic state16. The volatile
agent had been previously turned off;
therefore, the circuit was flushed with
high oxygen flows and reconnected
to the patient. It is not recommended
to waste time changing anaesthetic
machine circuits1. The patient was
hyperventilated with 100 per cent
oxygen and fresh gas flows to aid in
the removal of CO2.
Administration of dantrolene is the
first line of treatment in a suspected
MH event. Dantrolene is a skeletal
muscle relaxant that works by
disrupting the release of calcium
from the sarcoplasmic reticulum
of skeletal muscle cells2. Prompt
administration of dantrolene restores
levels of calcium in skeletal muscle
cells and has a protective effect on
excitation of neurotransmitters17. A
total of 19 vials were intravenously
administered to the patient by
slow push via a peripheral line
until muscle rigidity symptoms
subsided. The patient’s vital signs
were continuously monitored and
documented within the operating
room. The remainder of the
dantrolene vials were sent with the
patient to the intensive care unit.
The mixing of the dantrolene is a
manually intensive task and required
multiple staff to assist.

At the peak of the emergency the
patient was sweating profusely.
His temperature reached 40° C.
Muscle rigidity causes rapid body
temperature increases due to the
increased cellular activity and
energy consumption16. An indwelling
bladder catheter was inserted in
theatre. This was done to monitor for
myoglobinuria (dark coloured urine)
and ensure adequate urine output1.
An arterial line was inserted in
intensive care to allow for continual
haemodynamic monitoring and
blood gas sampling. Due to the high
amounts of dantrolene requiring
administration, a central line was
inserted. Dantrolene can have a
necrotic effect on peripheral access
due to its high alkaline content2. The
initial management of the patient
in intensive care was to continue
dantrolene infusions, aggressive
management of temperature and
monitor pathology for hyperkalaemia,
coagulation parameters and
treatment of acidosis1.

Outcome and follow-up
The patient was transferred to the
intensive care unit at 11.50 pm
on Christmas Eve. He was placed
on a ventilator and was closely
monitored. He spent a total of five
days in intensive care, three of which
he remained ventilated. Sedation
was managed by propofol and
fentanyl infusions. Temperature was
continually monitored by core and
tympanic measurements. The patient
suffered three recurring events of
MH while in intensive care, when his
symptoms were managed by further
dantrolene administration. Each time
the patient’s temperature spiked, the
patient also became tachycardic and
hypertensive and his tremor returned.
Dantrolene doses were ceased
on the second night in intensive
care. The patient experienced no
further MH symptoms and was
successfully extubated the following

morning. Continuous monitoring
was performed as the patient was
very weak from the large doses
of dantrolene. The patient was
discharged to the surgical ward on
the fifth day and then discharged
home on day seven, suffering no
further symptoms of MH.

Discussion
The first documented case of
malignant hyperthermia in Australia
occurred in 19607. It was discovered
that ten out of 38 relatives of a
Melbourne family had died during
or following general anaesthesia18.
A genetic sensitivity was suspected
to be the cause of this disorder. By
the 1990s a genetic connection was
discovered linking calcium channels
in ryanodine receptors of skeletal
muscle (RYR1). Up to 70 per cent of
MH vulnerable individuals carry a
RYR1 mutation19. There are many
mutations of this receptor with only
50 per cent of patients carrying
known MH genes20. The severity of
the reaction depends on the location
of the protein mutation21. A patient
who records an unequivocal muscle
biopsy result needs to be treated
as susceptible9, 22. It is important
for clinicians to understand the
significance of genetic sequencing
specific to MH10.
Mortality rates have decreased since
the implementation of broader
anaesthetic techniques, improved
monitoring, increased awareness10
and newer generation muscle
relaxants that have fewer side effects
than suxamethonium8. Mortality rates
in the 1970s were almost 80 per cent;
with the introduction of dantrolene
these rates dropped to less than
15 per cent19. MH reactions do not
always occur on the first exposure to
anaesthetic drugs23. Some research
argues that a minimum of three
anaesthetics are needed to trigger
an event22. Mr M had been exposed
to sevoflurane during his dental
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extraction with no adverse effects.
The duration of the inhalational
exposure and the concentration of
gases delivered may explain why Mr
M did not have a MH reaction on his
first exposure23. This fact emphasises
the unpredictable nature that MH
presents to anaesthetic clinicians.
The circumstances discussed in this
case study are unique as this crisis
occurred in the late hours of the
night on Christmas Eve in a small
regional facility. There was minimal
staff present, none of which had
ever encountered this condition
before. The symptoms the patient
displayed did not become apparent
until the completion of his surgery.
The patient also experienced further
episodes while intubated in intensive
care. Recurrence of symptoms
can occur in up to 20 per cent of
cases24. Observation and monitoring
intra- and post-operatively is of
utmost importance as is knowing
the clinical signs of an unfolding
event. All staff that work within a
perioperative department should
be aware of the process to manage
a patient displaying indications of a
MH crisis7. Preparedness is the key to
management and recovery from the
effects of malignant hyperthermia.

being conducted. Understandably,
they were only willing to send
partial amounts of their stocks.
The remaining hospital stated that
they did not keep any stocks of
dantrolene. The hospital coordinator
was unaware of the importance
of dantrolene and its presence
in the operating theatre. MHANZ
recommend that facilities do not rely
on other hospitals for dantrolene
stock in crisis management11. Since
this event the hospital now stocks 36
ampoules of dantrolene.
The patient described in this case
study has not been involved in any
clinical trials. Genetic testing has not
yet been commenced due to family
commitments and distance from
testing facilities.

Implications for practice
Dantrolene stocks
A direct outcome of this emergency
was an increase in dantrolene stock
levels. As this facility is in a regional
location, the chief medical officer
decided to increase stock to 36 vials.
MHANZ recommend that in isolated
areas 36 vials should be kept to
ensure adequate stock if a crisis
occurs11.

Access to dantrolene

Education

For many years there has been an
agreement that each facility located
in the region stocked 12 ampoules
of dantrolene. If the need arises,
then the other facilities would
mobilise stock to the facility in
need. Dantrolene is an expensive
medication that has a short shelf life.
The facility at that time stocked 12
ampoules of dantrolene. Problems
began to occur when additional
stocks of dantrolene were attempted
to be mobilised from the other
facilities. The closest facility was
the day surgery hospital which was
closed for the holidays. A second
facility had surgical cases still

Anaesthetic emergencies often
present without warning and
require specialised skills to manage.
Simulation, problem solving25,
teamwork26, technical and nontechnical skills27 are all fundamental
aspects of specialised education
required for perioperative staff. All
perioperative staff are encouraged
to complete the online training
package prepared by MHANZ. Expired
stocks of dantrolene will be used to
illustrate the technique of drawing
up and administering the medication
in planned training scenarios. Early
treatment is the key to best patient
outcome.
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Anaesthetic nurse assessment
skills
Pre-anaesthetic assessment of
the patient is not only the role
of the anaesthetist. Indicators of
potential anaesthetic difficulties
need to be recognised during the
initial handover and assessment
of the patient. The anaesthetic
nurse is the first line of support
to the anaesthetist as anaesthetic
emergencies are generally
unpredictable and unforeseen.
Situational awareness and decisionmaking skills are non-technical
abilities that anaesthetic nurses
develop over time28. Systematic
assessment of the patient is a
fundamental skill that is based on
clinical knowledge and fine-tuned
with experience.
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